<div id="readability-page-1"><div>By Billy Gray Novartis said it expected a key profitability metric to decline this year in large part due to increased competition in the U.S. from generic drug competitors. The Swiss pharma major said Wednesday that it expects its core operating profit--one of its preferred metrics, which strips out exceptional items--for 2026 to decline by a low single digit. It expects low single-digit sales growth this year. Novartis said in the performance update that in 2026, it would face the largest drug-patent expiry headwind in its history. Three blockbuster treatments--Entresto, Promacta and Tasigna--lost U.S. patent exclusivity toward the middle of last year, which the group said was the primary catalyst of its guidance toward a short-term profitability fall. Increased competition from generic competitors would generate a roughly $4 billion negative impact in 2026, Harry Kirsch, Novartis's chief financial officer, said in a call with reporters. Fourth-quarter sales for the heart-failure treatment Entresto fell 45% on year at constant currency, to $1.25 billion, while Promacta sales for the period plunged 63% at constant exchange rates, to $226 million. Net sales in the fourth quarter fell 1% at constant currency compared with the prior-year period, to $13.34 billion, the company said. Still, Novartis reiterated that it expects sales to grow through 2030 at a compound annual rate of 5% to 6%. J.P. Morgan analysts said that would lead to a 9% consensus-estimate beat for 2030 sales that would require a number of successful treatment candidates in the pipeline. Changes to U.S. drug pricing to most-favored-nations levels didn't have a material effect on 2026 guidance, Chief Executive Vas Narasimhan said. The company said core operating profit for the year grew to $21.89 billion from $19.49 billion for the year prior, on sales that rose to $54.53 billion from $50.32 billion. Analysts polled by Visible Alpha had forecast $21.85 billion in core operating profit and $54.82 billion in sales. Write to Billy Gray at william.gray@wsj.com (END) Dow Jones Newswires02-04-26 0638ET</div></div>

諾華製藥預測，由於美國仿製藥競爭加劇，2026 年核心營業利潤將出現下降，預計降幅為低個位數。該公司面臨重大專利到期，尤其是像 Entresto 和 Promacta 這樣的暢銷藥物，已經出現了顯著的銷售下降。儘管如此，諾華預計到 2030 年年均銷售增長將達到 5-6%。第四季度銷售略微下降至 133.4 億美元，但核心營業利潤上升至 218.9 億美元，略高於分析師預期

Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S. -- Update

marketscreener

諾華制藥

標普生物技術 3 倍做空 - Direxion

鵬華上證科創板生物醫藥ETF

美國制藥 ETF - iShares

廣發中證香港創新藥(QDII-ETF)

2 倍做多納斯達克生物技術 ETF - ProShares

生物科技 ETF - VanEck Vectors

平安中證醫療創新ETF

創新藥

醫藥突破 ETF - ALPS

招商中證生物科技主題ETF

醫療業 ETF - SPDR

易方達恆生港股通創新藥ETF

醫療業 ETF - Vanguard

易方達中證生物科技主題ETF

國泰中證生物醫藥ETF

華夏中證生物科技主題ETF

Invesco Nasdaq Biotechnology ETF

天弘國證生物醫藥ETF

博時恆生港股通創新藥精選ETF

易方達滬深300醫藥ETF

納斯達克生物科技指數 ETF - iShares Nasdaq

南方恆生生物科技ETF(QDII)

標普生物技術 ETF - SPDR

方正富邦中證醫藥及醫療器械創新ETF

香港醫藥

博時恆生醫療保健(QDII-ETF)

生物科技ETF基金

華夏上證科創板生物醫藥ETF

動態生物技術與基因組 ETF - Invesco

科創醫藥ETF工銀

富國恆生港股通創新藥及醫療保健ETF

基因改革 ETF - ARK

華寶恆生港股通創新藥精選ETF

諾發集團

紐交所高增長板生物技術指數 ETF - First Trust

華夏醫藥ETF

標普全球醫療股指數 ETF - iShares

華安恆生生物科技ETF

諾華製藥預測美國市場的仿製藥競爭將對其盈利能力造成衝擊 -- 更新